Page 84 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition

Declaration of interests
Participants of the Technical Consultation on the review of the WHO Guidelines for the
Treatment of Malaria and the external expert reviewers of the guidelines reported relevant
interests, in accordance with WHO procedures. These were discussed extensively by the
committee. Although it was considered that none of these declared interests had any
direct relevance to the deliberations and recommendations of the meeting, those panel
members with declared interests were excluded from the GRADE and recommendations
sub-committee and the guidelines drafting sub-committee. The declared interest, as per
WHO regulations, was cleared through the Legal Department of WHO.

Dr N. Valecha reported serving as an investigator for clinical trials supported by the
Medicine for Malaria Venture (MMV), the Drugs for Neglected Diseases initiative (DNDi)
and Ranbaxy Laboratories Limited. There were no monetary benefits and no conflicts
with the subject of this review.
Dr L. Sluscker reported having collaborated with the Kenya Medical Research Institute
on a study of paediatric Coartem®. The CDC did not receive funds from the manufacturer
(Novartis Pharma AG).
Professor A. Bjorkman reported having participated in a study on paediatric Coartem®
sponsored by Novartis Pharma AG.
Dr K. Barnes reported being a grants co-recipient from the Global Fund to Fight AIDS,
Tuberculosis and Malaria (GFATM), the Bill and Melinda Gates Foundation (BMGF)
and the UK Department for International Development (DfiD) to evaluate antimalarial
medicines.

Dr G. Mokuolu reported being a co-investigator in a multi-centre study comparing
intravenous artesunate and quinine for the treatment of severe malaria in African
children. The study is funded by Oxford University, the United Kingdom.
Dr F. ter-Kuile reported grant income from two not-for-profit project drug developers
(MMV and DNDi). He also received a previous grant from Novartis Pharma AG, and
is currently serving on the Coartem® advisory board for Novartis.
Dr D. Terlouw reported receiving research funding from an organization that supports
the development of drugs for tropical diseases, including malaria.
All other members of the committee reported no interests.

70